Stock 1873 VIVA BIOTECH HOLDINGS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Viva Biotech Holdings

Equities

1873

KYG9390W1015

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:34 21/06/2024 pm IST 		5-day change 1st Jan Change
0.53 HKD 0.00% Intraday chart for Viva Biotech Holdings -13.11% -49.52%
28/03 Viva Biotech Holdings Reports Earnings Results for the Full Year Ended December 31, 2023 CI
18/01 Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 6,365 14,722 7,370 2,960 2,044
Enterprise Value (EV) 1 5,480 15,334 9,224 5,105 2,911
P/E ratio 22.6 x -30.8 x 46.5 x -5.52 x -6.67 x
Yield 0.44% 0.3% - - -
Capitalization / Revenue 19.7 x 21.1 x 3.5 x 1.24 x 0.95 x
EV / Revenue 17 x 22 x 4.38 x 2.15 x 1.35 x
EV / EBITDA 77.4 x 93.5 x 24.9 x 11.7 x 7.44 x
EV / FCF -97.9 x -18.9 x -21.5 x 1,917 x 20.3 x
FCF Yield -1.02% -5.28% -4.65% 0.05% 4.93%
Price to Book 3.58 x 3.91 x 1.88 x 0.82 x 0.55 x
Nbr of stocks (in thousands) 15,61,818 19,13,823 19,20,328 19,15,437 21,41,766
Reference price 2 4.075 7.693 3.838 1.546 0.9544
Announcement Date 28/04/20 28/04/21 28/04/22 26/04/23 26/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 210 323.1 697 2,104 2,380 2,156
EBITDA 1 60.25 70.78 164.1 369.9 436.4 391
EBIT 1 50.7 54.32 112.5 236.9 266 192.7
Operating Margin 24.14% 16.81% 16.15% 11.26% 11.18% 8.94%
Earnings before Tax (EBT) 1 105.9 280.9 -356.2 347.7 -459.2 -55.95
Net income 1 90.55 265.9 -386.9 287.5 -528.5 -116.1
Net margin 43.11% 82.3% -55.51% 13.67% -22.21% -5.39%
EPS 2 0.0800 0.1800 -0.2500 0.0826 -0.2800 -0.1432
Free Cash Flow 1 -15.29 -55.99 -809.5 -429.1 2.663 143.5
FCF margin -7.28% -17.33% -116.15% -20.39% 0.11% 6.65%
FCF Conversion (EBITDA) - - - - 0.61% 36.69%
FCF Conversion (Net income) - - - - - -
Dividend per Share - 0.0179 0.0234 - - -
Announcement Date 05/03/19 28/04/20 28/04/21 28/04/22 26/04/23 26/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 S1
Net sales 1 1,142
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income -
Net margin -
EPS 2 0.001000
Dividend per Share -
Announcement Date 29/08/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 67.4 - 612 1,854 2,144 867
Net Cash position 1 - 884 - - - -
Leverage (Debt/EBITDA) 1.119 x - 3.727 x 5.011 x 4.914 x 2.217 x
Free Cash Flow 1 -15.3 -56 -809 -429 2.66 143
ROE (net income / shareholders' equity) 44.8% 26.2% -13.7% 7.84% -13.4% -2.74%
ROA (Net income/ Total Assets) 8.66% 2.8% 1.4% 1.83% 2.08% 1.57%
Assets 1 1,045 9,508 -27,648 15,730 -25,378 -7,410
Book Value Per Share 2 0.2300 1.140 1.970 2.040 1.880 1.720
Cash Flow per Share 2 0.1400 0.5800 1.210 0.4200 0.3500 0.4800
Capex 1 46.9 56.2 593 565 249 188
Capex / Sales 22.33% 17.39% 85.03% 26.86% 10.48% 8.71%
Announcement Date 05/03/19 28/04/20 28/04/21 28/04/22 26/04/23 26/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
VIVA BIOTECH HOLDINGS Stock Viva Biotech Holdings
-49.52% 15Cr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.93% 80TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.51% 63TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.10% 36TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.53% 33TCr
ABBVIE INC. Stock AbbVie Inc.
+10.12% 30TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.66% 24TCr
ROCHE HOLDING AG Stock Roche Holding AG
+3.39% 23TCr
NOVARTIS AG Stock Novartis AG
+10.75% 22TCr
AMGEN INC. Stock Amgen Inc.
+6.84% 17TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1873 Stock
  4. Financials Viva Biotech Holdings